SCHEMBL5147101

SCHEMBL5147101

CC(N)CC(C)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19292743 1.00
Hydrochloric Acid SCHEMBL30319513 0.97 ENPEP (0.58)
Hydrochloric Acid SCHEMBL30319514 0.97 ENPEP (0.58)
SCHEMBL23924659 0.87 ENPEP (0.54)
SCHEMBL6668940 0.83
SCHEMBL7314519 0.82 NAALAD2 (0.56)
SCHEMBL10938417 0.82 NAALAD2 (0.56)
SCHEMBL443229 0.82 NAALAD2 (0.56)
2S,4R-4-Methylglutamate SCHEMBL7064898 0.81 SLC7A5 (0.68)
2S,4R-4-Methylglutamate SCHEMBL1133372 0.81 SLC7A5 (0.68)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117343920-A Aminotransferase, nucleic acid molecule, recombinant expression vector and application thereof 浙江赞源生物技术有限公司 2024-01-05 CN claimed
CN-118434765-A BCMA monoclonal antibodies and antibody-drug conjugates 杭州多禧生物科技有限公司 2024-08-02 CN disclosed
CN-117343920-A Aminotransferase, nucleic acid molecule, recombinant expression vector and application thereof 浙江赞源生物技术有限公司 2024-01-05 CN disclosed
CN-116751135-A Preparation method of Sakuba/valsartan sodium 苏州东瑞制药有限公司 2023-09-15 CN disclosed
CN-108602785-B Novel processes and intermediates 诺华股份有限公司 2023-08-11 CN disclosed
CN-115772509-A Transaminase mutant and coding gene and application thereof 广东东阳光药业有限公司 2023-03-10 CN disclosed
CN-113453724-A Sulfonylmaleimide-based linkers and corresponding conjugates 皮埃尔法布雷医药公司 2021-09-28 CN disclosed
CN-110964759-B Novel synthesis process of anti-heart-failure drug intermediate 北京瑞莱博基医药科技有限公司 2021-04-09 CN disclosed
US-10752705-B2 Oligosaccharide compositions and methods for producing thereof CADENA BIO, INC. (US) 2020-08-25 US disclosed
CN-106521716-B Modification of continuous carbon fibers during precursor formation for composite materials with enhanced moldability 通用汽车环球科技运作有限责任公司 2020-05-19 CN disclosed
CN-110964759-A Novel synthesis process of anti-heart-failure drug intermediate 北京瑞莱博基医药科技有限公司 2020-04-07 CN disclosed
CN-106521716-A Modification of continuous carbon fibers during precursor formation for composites having enhanced moldability 通用汽车环球科技运作有限责任公司 2017-03-22 CN disclosed
WO-2010010080-A1 ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS BRACCO IMAGING SPA (IT) 2010-01-28 WO disclosed
WO-2010010079-A1 DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES BRACCO IMAGING SPA (IT) 2010-01-28 WO disclosed
US-20070072096-A1 Negative curable dye-containing composition, color filter, and method of manufacturing the same FUJI PHOTO FILM CO., LTD. 2007-03-29 US disclosed
US-4966856-A QUANTITATIVE ANALYSIS OF FLUID SAMPLES KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1990-10-30 US disclosed